Understanding rejection in uterine transplantation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to investigate the immunological mechanisms behind rejection in uterine transplantation and identify non-invasive markers for rejection. Researchers will collect biological samples, including blood, biopsies, and vaginal swabs, from a cohort of patients who have received or donated a uterus, as well as control participants. The study will utilize transcriptomics and microbiota analysis to explore differences among the groups. By focusing on minimally invasive sample collection, the study seeks to enhance patient comfort while gathering essential data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient going to or having received a uterine transplant OR Patient going to or having donated a uterus for a recipient included in the study OR Premenopausal woman to undergo gynecological surgery under general anesthesia: for 4 of them it was a hysterectomy and they must be under 45 years old, the other 6 must be under 38 years old.

Exclusion Criteria (For witness):

* Pregnancy in progress
* Current infection
* Cervical dysplasia
* History of transplant or transfusion
* Cancer or history of cancer
* Menopause
* Patient aged 38 or over for the 6 controls without hysterectomy, patient aged 45 or over for the 4 patients with hysterectomy.
* Endometriosis

Where it's running

• Hopital Foch
  Suresnes, France Recruiting

Study contacts

• Principal investigator: Jean-Marc Ayoubi, MD, PhD — Hopital Foch
• Study coordinator: Marie Carbonnel, MD
• Email: m.carbonnel@hopital-foch.com
• Phone: +331 46 25 48 53

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating cell-free DNA in kidney transplant patients

  This study is testing a new method to see if analyzing DNA in blood and urine can help doctors detect kidney transplant rejection earlier in patients who are having a biopsy.

  Recruiting CGenetix · Rouen · NCT06910527

• Tezepelumab for chronic bronchial disease due to BOS after allogeneic stem cell transplant

  This study tests whether tezepelumab can help adults with bronchial obstruction caused by bronchiolitis obliterans syndrome after an allogeneic stem cell transplant.

  Recruiting Phase 2 Hopital Foch · Besançon and 5 other locations · NCT07771855

• SCENAR therapy for chronic neck pain

  This study tests whether repeating SCENAR therapy can reduce disability and pain for adults with long-standing non-specific neck pain.

  Recruiting Hopital Foch · Suresnes, Île-de-France Region · NCT07742228

• Evaluating the effects of dostarlimab and vitamin D3 with mFOLFIRINOX in pancreatic cancer

  This study is testing a new combination of a cancer drug, vitamin D3, and chemotherapy to see if it can help people with untreated advanced pancreatic cancer.

  Recruiting Phase 2 Hopital Foch · Marseille and 4 other locations · NCT06757244

• Assessing late images in PET-CT for bladder cancer staging

  This study is testing if taking later images during a PET-CT scan can help better identify lymph node involvement in patients with muscle-invasive bladder cancer.

  Recruiting Hopital Foch · Suresnes, Île-de-France Region · NCT06537960

• Comparing two methods for securing intubation tubes

  This study is testing whether a new device for securing breathing tubes works better than the usual method to help prevent complications for patients in intensive care.

  Recruiting Hopital Foch · Suresnes · NCT06533436

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.